FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2095031836> ?p ?o ?g. }

• W2095031836 endingPage "1666" @default.
• W2095031836 startingPage "1666" @default.
• W2095031836 abstract "Since October, 1999, wild poliovirus type 2 has not been detected in community-acquired infection anywhere, despite eradication-quality surveillance.1Anon Apparent global interruption of wild poliovirus type 2 transmission.MMWR Morb Mortal Wkly Rep. 2001; 50: 222-224PubMed Google Scholar We can, therefore, be confident that the virus has been globally eradicated, giving us the first reason to drop the type 2 component from the oral polio vaccine.The second reason is more important. Vaccine viruses are genetic mutants of wild virus strains, with greatly reduced neurovirulence and transmissibility. Neurovirulence can increase as a result of back-mutations, occurring during replication and transmission. As such, oral polio vaccine can give rise to rare sporadic vaccine-associated paralytic polio (VAPP) in vaccinated children or in unvaccinated contacts. If transmissibility is regained, the resultant circulating vaccine-derived poliovirus (cVDPV) could cause outbreaks of VAPP.2Kew OM Wright PF Agol VI et al.Circulating vaccine-derived polioviruses: current state of knowledge.Bull World Health Organ. 2004; 82: 16-23PubMed Google Scholar Reduced immunisation coverage in a community results in children who are shedding vaccine virus coming into contact with those not immunised against polio, providing an optimum environment for the emergence of cVDPVs.2Kew OM Wright PF Agol VI et al.Circulating vaccine-derived polioviruses: current state of knowledge.Bull World Health Organ. 2004; 82: 16-23PubMed Google Scholar In the past, all children not immunised would have been protected through contact with wild viruses. We cannot predict the probability of emergence of cVDPV if oral polio vaccine was stopped in the posteradication era, when birth cohorts will have no immunity from vaccine or wild virus infection. The eradication of type 2 wild virus offers an opportunity to assess this risk by discontinuing type-specific vaccine while surveillance quality remains excellent.Those involved in the Global Polio Eradication Initiative and other science opinion leaders and representatives of agencies that have funded the global mission, should meet urgently to discuss this possibility. If all agree, oral polio vaccine without type 2 should be manufactured and licensed with minimum lead-time. Since October, 1999, wild poliovirus type 2 has not been detected in community-acquired infection anywhere, despite eradication-quality surveillance.1Anon Apparent global interruption of wild poliovirus type 2 transmission.MMWR Morb Mortal Wkly Rep. 2001; 50: 222-224PubMed Google Scholar We can, therefore, be confident that the virus has been globally eradicated, giving us the first reason to drop the type 2 component from the oral polio vaccine. The second reason is more important. Vaccine viruses are genetic mutants of wild virus strains, with greatly reduced neurovirulence and transmissibility. Neurovirulence can increase as a result of back-mutations, occurring during replication and transmission. As such, oral polio vaccine can give rise to rare sporadic vaccine-associated paralytic polio (VAPP) in vaccinated children or in unvaccinated contacts. If transmissibility is regained, the resultant circulating vaccine-derived poliovirus (cVDPV) could cause outbreaks of VAPP.2Kew OM Wright PF Agol VI et al.Circulating vaccine-derived polioviruses: current state of knowledge.Bull World Health Organ. 2004; 82: 16-23PubMed Google Scholar Reduced immunisation coverage in a community results in children who are shedding vaccine virus coming into contact with those not immunised against polio, providing an optimum environment for the emergence of cVDPVs.2Kew OM Wright PF Agol VI et al.Circulating vaccine-derived polioviruses: current state of knowledge.Bull World Health Organ. 2004; 82: 16-23PubMed Google Scholar In the past, all children not immunised would have been protected through contact with wild viruses. We cannot predict the probability of emergence of cVDPV if oral polio vaccine was stopped in the posteradication era, when birth cohorts will have no immunity from vaccine or wild virus infection. The eradication of type 2 wild virus offers an opportunity to assess this risk by discontinuing type-specific vaccine while surveillance quality remains excellent. Those involved in the Global Polio Eradication Initiative and other science opinion leaders and representatives of agencies that have funded the global mission, should meet urgently to discuss this possibility. If all agree, oral polio vaccine without type 2 should be manufactured and licensed with minimum lead-time." @default.
• W2095031836 created "2016-06-24" @default.
• W2095031836 creator A5018534101 @default.
• W2095031836 date "2004-11-01" @default.
• W2095031836 modified "2023-10-03" @default.
• W2095031836 title "Two good reasons to drop type 2 virus from oral polio vaccine" @default.
• W2095031836 cites W2107407339 @default.
• W2095031836 doi "https://doi.org/10.1016/s0140-6736(04)17351-0" @default.
• W2095031836 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15530625" @default.
• W2095031836 hasPublicationYear "2004" @default.
• W2095031836 type Work @default.
• W2095031836 sameAs 2095031836 @default.
• W2095031836 citedByCount "7" @default.
• W2095031836 countsByYear W20950318362013 @default.
• W2095031836 countsByYear W20950318362022 @default.
• W2095031836 countsByYear W20950318362023 @default.
• W2095031836 crossrefType "journal-article" @default.
• W2095031836 hasAuthorship W2095031836A5018534101 @default.
• W2095031836 hasConcept C116675565 @default.
• W2095031836 hasConcept C119599485 @default.
• W2095031836 hasConcept C127413603 @default.
• W2095031836 hasConcept C159047783 @default.
• W2095031836 hasConcept C22070199 @default.
• W2095031836 hasConcept C2522874641 @default.
• W2095031836 hasConcept C2776811989 @default.
• W2095031836 hasConcept C2779631682 @default.
• W2095031836 hasConcept C4870876 @default.
• W2095031836 hasConcept C71924100 @default.
• W2095031836 hasConcept C761482 @default.
• W2095031836 hasConcept C86803240 @default.
• W2095031836 hasConceptScore W2095031836C116675565 @default.
• W2095031836 hasConceptScore W2095031836C119599485 @default.
• W2095031836 hasConceptScore W2095031836C127413603 @default.
• W2095031836 hasConceptScore W2095031836C159047783 @default.
• W2095031836 hasConceptScore W2095031836C22070199 @default.
• W2095031836 hasConceptScore W2095031836C2522874641 @default.
• W2095031836 hasConceptScore W2095031836C2776811989 @default.
• W2095031836 hasConceptScore W2095031836C2779631682 @default.
• W2095031836 hasConceptScore W2095031836C4870876 @default.
• W2095031836 hasConceptScore W2095031836C71924100 @default.
• W2095031836 hasConceptScore W2095031836C761482 @default.
• W2095031836 hasConceptScore W2095031836C86803240 @default.
• W2095031836 hasIssue "9446" @default.
• W2095031836 hasLocation W20950318361 @default.
• W2095031836 hasLocation W20950318362 @default.
• W2095031836 hasOpenAccess W2095031836 @default.
• W2095031836 hasPrimaryLocation W20950318361 @default.
• W2095031836 hasRelatedWork W2032866374 @default.
• W2095031836 hasRelatedWork W2085535385 @default.
• W2095031836 hasRelatedWork W2088363170 @default.
• W2095031836 hasRelatedWork W2101342567 @default.
• W2095031836 hasRelatedWork W2169451742 @default.
• W2095031836 hasRelatedWork W2401086633 @default.
• W2095031836 hasRelatedWork W4293704970 @default.
• W2095031836 hasRelatedWork W4309437577 @default.
• W2095031836 hasRelatedWork W4385491733 @default.
• W2095031836 hasRelatedWork W2769038553 @default.
• W2095031836 hasVolume "364" @default.
• W2095031836 isParatext "false" @default.
• W2095031836 isRetracted "false" @default.
• W2095031836 magId "2095031836" @default.
• W2095031836 workType "article" @default.